A Phase 1 Placebo-controlled Study of the Safety and Tolerability of Rectally Administered, Multiple-ascending Doses of IW-3300 in Healthy Subjects
Latest Information Update: 05 Feb 2024
At a glance
- Drugs IW-3300 (Primary)
- Indications Interstitial cystitis
- Focus Adverse reactions
- Sponsors Ironwood Pharmaceuticals
Most Recent Events
- 04 Aug 2022 Status changed from recruiting to completed, according to a Ironwood Pharmaceuticals media release.
- 08 Jun 2022 Status changed from not yet recruiting to recruiting.
- 11 May 2022 New trial record